Fan R-F, Chai F-L, He G-X, Wei L-X, Li R-Z, Wan W-X, Bai M-D, Zhu W-K, Cao M-L, Li H-M, Yan S-Z
Department of Hepatobiliary Surgery, Lanzhou General Hospital of Lanzhou Military Region, People's Liberation Army, No. 58 Western Xiaoxihu Street, Lanzhou, 730050, Gansu, People's Republic of China.
Surg Endosc. 2006 Feb;20(2):281-5. doi: 10.1007/s00464-005-0184-8. Epub 2005 Dec 9.
Radiofrequency ablation (RFA), currently used extensively for liver tumors, also has been applied successfully to hepatic cavernous hemangioma (HCH) percutaneously. The aim of this study was to assess the feasibility, safety, and efficacy of laparoscopic RFA for patients with HCHs.
Between March 2001 and March 2004, 27 patients with symptomatic and rapid-growth lesions were treated by laparoscopic RFA using the RF-2000 generator system. The treatment-related complications were observed. All the patients were followed up with helical computed tomography scans and ultrasonography at regular intervals to assess the therapeutic efficacy of laparoscopic RFA.
This study assessed 9 men and 18 women with a mean age of 41.6 +/- 8.3 years. Three additional intrahepatic lesions missed preoperatively were found in three patients on intraoperative ultrasound. A total of 27 patients with 50 liver lesions were treated successfully with laparoscopic RFA. The mean maximum tumor diameter was 5.5 +/- 2.0 cm. The mean length of time for RFA per lesion was 20.7 +/- 11.9 min, and the mean blood loss was 134.4 +/- 88.9 ml. Laparoscopic cholecystectomy was performed simultaneously for gallstones in 13 patients and for abutting of gallbladder from hemangioma in 2 patients. In addition, 3 patients also had a laparoscopic deroofing of simple hepatic cysts. Although postoperative low-grade fever and transient elevation of serum transaminase levels were observed in 13 patients, there were no complications related to laparoscopic RFA. During a median follow-up period of 21 months (range, 12-42 months), complete lesion necrosis was achieved for all the patients.
Laparoscopic RFA therapy is a safe, feasible, and effective treatment option for patients with symptomatic and rapid-growth HCHs located on the surface of the liver or adjacent to the gallbladder. Intraoperative ultrasonography is a useful adjunct for detecting additional liver lesions and offering more accurate targeting for RFA.
射频消融(RFA)目前广泛应用于肝脏肿瘤,也已成功地经皮应用于肝海绵状血管瘤(HCH)。本研究的目的是评估腹腔镜RFA治疗HCH患者的可行性、安全性和有效性。
2001年3月至2004年3月,27例有症状且病变快速生长的患者采用RF - 2000发生器系统进行腹腔镜RFA治疗。观察治疗相关并发症。所有患者定期接受螺旋CT扫描和超声检查,以评估腹腔镜RFA的治疗效果。
本研究评估了9例男性和18例女性,平均年龄41.6±8.3岁。术中超声检查发现3例患者术前漏诊的另外3个肝内病变。27例共50个肝脏病变患者成功接受了腹腔镜RFA治疗。肿瘤平均最大直径为5.5±2.0 cm。每个病变的RFA平均时间为20.7±11.9分钟,平均失血量为134.4±88.9 ml。13例患者因胆结石同时行腹腔镜胆囊切除术,2例患者因血管瘤与胆囊毗邻而行腹腔镜胆囊切除术。此外,3例患者还接受了腹腔镜单纯性肝囊肿去顶术。虽然13例患者术后出现低热和血清转氨酶水平短暂升高,但无腹腔镜RFA相关并发症。在中位随访期21个月(范围12 - 42个月)内,所有患者均实现病变完全坏死。
腹腔镜RFA治疗是位于肝脏表面或毗邻胆囊的有症状且快速生长的HCH患者的一种安全、可行且有效的治疗选择。术中超声检查有助于发现额外的肝脏病变,并为RFA提供更精确的靶点。